{"brief_title": "The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic", "brief_summary": "To determine the safety and efficacy of erythropoietin administered to patients with AIDS or advanced AIDS related complex ARC and anemia.", "condition": "Cytopenias", "intervention_type": "Drug", "intervention_name": "Epoetin alfa", "criteria": "Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - History of any primary hematologic disease. - Clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying HIV disease. - AIDS-related dementia. - Uncontrolled hypertension (diastolic blood pressure > 100 mmHg). - Presence of concomitant iron deficiency. - Anemia attributable to factors other than AIDS or zidovudine (AZT) therapy. - Acute opportunistic infection. - History of seizures. Concurrent Medication: Excluded: - Zidovudine (AZT) during the double-blind phase of the study. Patients with clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying AIDS are excluded. Prior Medication: Excluded within 30 days of study entry: - Experimental drug or experimental device. - Cytotoxic chemotherapy. - Excluded within 2 months of study entry: - Androgen therapy. - Zidovudine (AZT) and during double-blind phase of study. Clinical diagnosis of AIDS related anemia. - Clinical diagnosis of AIDS or advanced AIDS related complex (ARC). - Clinically stable for 1 month preceding study entry. Substance abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00002303.xml"}